These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

216 related articles for article (PubMed ID: 30130544)

  • 1. Patterns of Relapse and Implications for Post-Nephrectomy Surveillance in Patients with High Risk Nonclear Cell Renal Cell Carcinoma: Subgroup Analysis of the Phase 3 ECOG-ACRIN E2805 Trial.
    Narayan V; Puligandla M; Haas NB; Subramanian P; DiPaola RS; Uzzo R
    J Urol; 2019 Jan; 201(1):62-68. PubMed ID: 30130544
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Local Recurrence Following Resection of Intermediate-High Risk Nonmetastatic Renal Cell Carcinoma: An Anatomical Classification and Analysis of the ASSURE (ECOG-ACRIN E2805) Adjuvant Trial.
    Lee Z; Jegede OA; Haas NB; Pins MR; Messing EM; Manola J; Wood CG; Kane CJ; Jewett MAS; Flaherty KT; Dutcher JP; DiPaola RS; Uzzo RG
    J Urol; 2020 Apr; 203(4):684-689. PubMed ID: 31596672
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Tumor Microvessel Density as a Prognostic Marker in High-Risk Renal Cell Carcinoma Patients Treated on ECOG-ACRIN E2805.
    Jilaveanu LB; Puligandla M; Weiss SA; Wang XV; Zito C; Flaherty KT; Boeke M; Neumeister V; Camp RL; Adeniran A; Pins M; Manola J; DiPaola RS; Haas NB; Kluger HM
    Clin Cancer Res; 2018 Jan; 24(1):217-223. PubMed ID: 29066509
    [No Abstract]   [Full Text] [Related]  

  • 4. Retroperitoneal Lymphadenectomy for High Risk, Nonmetastatic Renal Cell Carcinoma: An Analysis of the ASSURE (ECOG-ACRIN 2805) Adjuvant Trial.
    Ristau BT; Manola J; Haas NB; Heng DYC; Messing EM; Wood CG; Kane CJ; DiPaola RS; Uzzo RG
    J Urol; 2018 Jan; 199(1):53-59. PubMed ID: 28728992
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cystic Renal Cell Carcinoma: A Report on Outcomes of Surgery and Active Surveillance in Patients Retrospectively Identified on Pretreatment Imaging.
    Kashan M; Ghanaat M; Hötker AM; Duzgol C; Sanchez A; DiNatale RG; Blum KA; Becerra MF; Manley BJ; Casuscelli J; Chiok M; Coleman JA; Russo P; Tickoo SK; Akin O; Hakimi AA
    J Urol; 2018 Aug; 200(2):275-282. PubMed ID: 29496470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Angiogenic Factor and Cytokine Analysis among Patients Treated with Adjuvant VEGFR TKIs in Resected Renal Cell Carcinoma.
    Xu W; Puligandla M; Manola J; Bullock AJ; Tamasauskas D; McDermott DF; Atkins MB; Haas NB; Flaherty K; Uzzo RG; Dutcher JP; DiPaola RS; Bhatt RS
    Clin Cancer Res; 2019 Oct; 25(20):6098-6106. PubMed ID: 31471309
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Sorafenib or sunitinib as postoperative adjuvant therapy for Chinese patients with locally advanced clear cell renal cell carcinoma at high risk for disease recurrence.
    Zhao J; Zhu Y; Zhang C; Wang X; He H; Wang H; Wu Y; Zhou W; Shen Z
    Urol Oncol; 2013 Nov; 31(8):1800-5. PubMed ID: 22658883
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adjuvant Vascular Endothelial Growth Factor-targeted Therapy in Renal Cell Carcinoma: A Systematic Review and Pooled Analysis.
    Sun M; Marconi L; Eisen T; Escudier B; Giles RH; Haas NB; Harshman LC; Quinn DI; Larkin J; Pal SK; Powles T; Ryan CW; Sternberg CN; Uzzo R; Choueiri TK; Bex A
    Eur Urol; 2018 Nov; 74(5):611-620. PubMed ID: 29784193
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term Risk of Recurrence in Surgically Treated Renal Cell Carcinoma: A Post Hoc Analysis of the Eastern Cooperative Oncology Group-American College of Radiology Imaging Network E2805 Trial Cohort.
    Jamil ML; Keeley J; Sood A; Dalela D; Arora S; Peabody JO; Trinh QD; Menon M; Rogers CG; Abdollah F
    Eur Urol; 2020 Feb; 77(2):277-281. PubMed ID: 31703971
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adjuvant therapy in patients with sarcomatoid renal cell carcinoma: post hoc analysis from Eastern Cooperative Oncology Group-American College of Radiology Imaging Network (ECOG-ACRIN) E2805.
    Karam JA; Puligandla M; Flaherty KT; Uzzo RG; Matin SF; Pins MR; Wood CG; Kane C; Jewett MAS; Kim SE; Dutcher JP; DiPaola RS; Haas NB
    BJU Int; 2022 Jun; 129(6):718-722. PubMed ID: 34480522
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cytoreductive nephrectomy for metastatic renal cell carcinoma with nonclear cell histology.
    Kassouf W; Sanchez-Ortiz R; Tamboli P; Tannir N; Jonasch E; Merchant MM; Matin S; Swanson DA; Wood CG
    J Urol; 2007 Nov; 178(5):1896-900. PubMed ID: 17868729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Adjuvant Sunitinib for High-risk Renal Cell Carcinoma After Nephrectomy: Subgroup Analyses and Updated Overall Survival Results.
    Motzer RJ; Ravaud A; Patard JJ; Pandha HS; George DJ; Patel A; Chang YH; Escudier B; Donskov F; Magheli A; Carteni G; Laguerre B; Tomczak P; Breza J; Gerletti P; Lechuga M; Lin X; Casey M; Serfass L; Pantuck AJ; Staehler M
    Eur Urol; 2018 Jan; 73(1):62-68. PubMed ID: 28967554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Plasma KIM-1 Is Associated with Recurrence Risk after Nephrectomy for Localized Renal Cell Carcinoma: A Trial of the ECOG-ACRIN Research Group (E2805).
    Xu W; Puligandla M; Halbert B; Haas NB; Flaherty KT; Uzzo RG; Dutcher JP; DiPaola RS; Sabbisetti V; Bhatt RS
    Clin Cancer Res; 2021 Jun; 27(12):3397-3403. PubMed ID: 33832947
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neutrophil-to-Lymphocyte Ratio as a Prognostic Factor of Disease-free Survival in Postnephrectomy High-risk Locoregional Renal Cell Carcinoma: Analysis of the S-TRAC Trial.
    Patel A; Ravaud A; Motzer RJ; Pantuck AJ; Staehler M; Escudier B; Martini JF; Lechuga M; Lin X; George DJ
    Clin Cancer Res; 2020 Sep; 26(18):4863-4868. PubMed ID: 32546645
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Axial Abdominal Imaging after Partial Nephrectomy for T1 Renal Cell Carcinoma Surveillance.
    Sorokin I; Canvasser NE; Margulis V; Lotan Y; Raj G; Sagalowsky A; Gahan JC; Cadeddu JA
    J Urol; 2017 Nov; 198(5):1021-1026. PubMed ID: 28442383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Adjuvant therapy in renal cell carcinoma: is resection still solely enough?
    Gharib KE
    Future Oncol; 2021 Feb; 17(6):633-636. PubMed ID: 33305597
    [No Abstract]   [Full Text] [Related]  

  • 17. Guidelines for the surveillance of localized renal cell carcinoma based on the patterns of relapse after nephrectomy.
    Stephenson AJ; Chetner MP; Rourke K; Gleave ME; Signaevsky M; Palmer B; Kuan J; Brock GB; Tanguay S
    J Urol; 2004 Jul; 172(1):58-62. PubMed ID: 15201737
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Fatigue among patients with renal cell carcinoma receiving adjuvant sunitinib or sorafenib: patient-reported outcomes of ECOG-ACRIN E2805 trial.
    Zhao F; Cella D; Manola J; DiPaola RS; Wagner LI; Haas NSB
    Support Care Cancer; 2018 Jun; 26(6):1889-1895. PubMed ID: 29274030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of Stereotactic Body Radiation Therapy for the Management of Oligometastatic Renal Cell Carcinoma.
    Franzese C; Franceschini D; Di Brina L; DʼAgostino GR; Navarria P; Comito T; Mancosu P; Tomatis S; Scorsetti M
    J Urol; 2019 Jan; 201(1):70-75. PubMed ID: 30577391
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Partial Nephrectomy is Associated with Higher Risk of Relapse Compared with Radical Nephrectomy for Clinical Stage T1 Renal Cell Carcinoma Pathologically Up Staged to T3a.
    Shah PH; Moreira DM; Patel VR; Gaunay G; George AK; Alom M; Kozel Z; Yaskiv O; Hall SJ; Schwartz MJ; Vira MA; Richstone L; Kavoussi LR
    J Urol; 2017 Aug; 198(2):289-296. PubMed ID: 28274620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.